Screener
Veracyte VCYT CapEx
CapEx at other companies
Other financials
Where this comes from
Reported directly by Veracyte in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.
The source filing: Veracyte’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 8:07 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001384101-26-000031
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net cash provided by operating activities | 35,215 | 5,362 |
| Investing activities | ||
| Purchase of short-term investments | (124,999) | (49,999) |
| Purchases of property, plant and equipment | (2,962) | (1,819) |
| Net cash used in investing activities | (127,961) | (51,818) |
| Financing activities | ||
| Payment of taxes on vested restricted stock units | (9,364) | (9,451) |
| Proceeds from the exercise of common stock options and employee stock purchases | 2,735 | 2,967 |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Veracyte's capex?
- Veracyte (VCYT) reported capex of $2.96M in Q1 2026.
- How has Veracyte's capex changed year-over-year?
- Veracyte's capex increased by 62.8% year-over-year, from $1.82M to $2.96M.
- What is the long-term trend for Veracyte's capex?
- Over 4 years (2021 to 2025), Veracyte's capex has grown at a 15.8% compound annual growth rate (CAGR), from $5.38M to $9.68M.
- What does capex mean?
- Cash spent on property, plant, and equipment — the primary measure of investment in productive capacity and infrastructure.
Ask your AI about Veracyte's capex.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude